Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | IM |
The patient received first dose of RabAvert on 23-May-2024, for rabies pre-exposure prophylaxis, and did not receive the second dose a week later; Case reference number US-BN-2024-001972 is a spontaneous case initially received from a consumer via Med Communications (reference number: USBAV24-1211) on 31-May-2024 and concerns female patient of unspecified age. The patient's relevant medical history and concomitant medication details were not provided. On 23-May-2024, reported as last Thursday, the patient was vaccinated with the first dose of RabAvert (batch number: unknown), intramuscularly, at an unknown dose, or site of administration for rabies pre-exposure prophylaxis. On an unspecified date, as reported yesterday, a week later, the patient did not receive the second dose of RabAvert (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert. No further information was provided.; Reporter's Comments: A female patient of unspecified age did not receive the second dose of RabAvert (week later than the first dose of RabAvert was administered intramuscularly, at an unknown dose, or site of administration for rabies pre-exposure prophylaxis) which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age did not receive the second dose of RabAvert (week later than the first dose of RabAvert was administered intramuscularly, at an unknown dose, or site of administration for rabies pre-exposure prophylaxis) which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.